Advanced

CSF and blood biomarkers for Parkinson's disease

Parnetti, Lucilla; Gaetani, Lorenzo; Eusebi, Paolo; Paciotti, Silvia; Hansson, Oskar LU ; El-Agnaf, Omar; Mollenhauer, Brit; Blennow, Kaj LU and Calabresi, Paolo (2019) In The Lancet Neurology 18(6). p.573-586
Abstract

In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers are urgently needed. The diagnosis of Parkinson's disease mostly relies on clinical symptoms, which hampers the detection of the earliest phases of the disease—the time at which treatment with forthcoming disease-modifying drugs could have the greatest therapeutic effect. Reliable prognostic markers could help in predicting the response to treatments. Evidence suggests potential diagnostic and prognostic value of CSF and blood biomarkers closely reflecting the pathophysiology of Parkinson's disease, such as α-synuclein species, lysosomal enzymes, markers of amyloid and tau pathology, and neurofilament light chain. A combination of multiple CSF... (More)

In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers are urgently needed. The diagnosis of Parkinson's disease mostly relies on clinical symptoms, which hampers the detection of the earliest phases of the disease—the time at which treatment with forthcoming disease-modifying drugs could have the greatest therapeutic effect. Reliable prognostic markers could help in predicting the response to treatments. Evidence suggests potential diagnostic and prognostic value of CSF and blood biomarkers closely reflecting the pathophysiology of Parkinson's disease, such as α-synuclein species, lysosomal enzymes, markers of amyloid and tau pathology, and neurofilament light chain. A combination of multiple CSF biomarkers has emerged as an accurate diagnostic and prognostic model. With respect to early diagnosis, the measurement of CSF α-synuclein aggregates is providing encouraging preliminary results. Blood α-synuclein species and neurofilament light chain are also under investigation because they would provide a non-invasive tool, both for early and differential diagnosis of Parkinson's disease versus atypical parkinsonian disorders, and for disease monitoring. In view of adopting CSF and blood biomarkers for improving Parkinson's disease diagnostic and prognostic accuracy, further validation in large independent cohorts is needed.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
The Lancet Neurology
volume
18
issue
6
pages
14 pages
publisher
Lancet Ltd
external identifiers
  • scopus:85065771657
ISSN
1474-4422
DOI
10.1016/S1474-4422(19)30024-9
language
English
LU publication?
yes
id
1e39b742-db65-4dcd-aca0-1fb79e7a4c0a
date added to LUP
2019-05-28 09:56:20
date last changed
2019-09-17 04:55:15
@article{1e39b742-db65-4dcd-aca0-1fb79e7a4c0a,
  abstract     = {<p>In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers are urgently needed. The diagnosis of Parkinson's disease mostly relies on clinical symptoms, which hampers the detection of the earliest phases of the disease—the time at which treatment with forthcoming disease-modifying drugs could have the greatest therapeutic effect. Reliable prognostic markers could help in predicting the response to treatments. Evidence suggests potential diagnostic and prognostic value of CSF and blood biomarkers closely reflecting the pathophysiology of Parkinson's disease, such as α-synuclein species, lysosomal enzymes, markers of amyloid and tau pathology, and neurofilament light chain. A combination of multiple CSF biomarkers has emerged as an accurate diagnostic and prognostic model. With respect to early diagnosis, the measurement of CSF α-synuclein aggregates is providing encouraging preliminary results. Blood α-synuclein species and neurofilament light chain are also under investigation because they would provide a non-invasive tool, both for early and differential diagnosis of Parkinson's disease versus atypical parkinsonian disorders, and for disease monitoring. In view of adopting CSF and blood biomarkers for improving Parkinson's disease diagnostic and prognostic accuracy, further validation in large independent cohorts is needed.</p>},
  author       = {Parnetti, Lucilla and Gaetani, Lorenzo and Eusebi, Paolo and Paciotti, Silvia and Hansson, Oskar and El-Agnaf, Omar and Mollenhauer, Brit and Blennow, Kaj and Calabresi, Paolo},
  issn         = {1474-4422},
  language     = {eng},
  number       = {6},
  pages        = {573--586},
  publisher    = {Lancet Ltd},
  series       = {The Lancet Neurology},
  title        = {CSF and blood biomarkers for Parkinson's disease},
  url          = {http://dx.doi.org/10.1016/S1474-4422(19)30024-9},
  volume       = {18},
  year         = {2019},
}